Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Standard Dose
600MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Prescription
Summary

Approval overview EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is listed in Drugs@FDA under application 201802 (ANDA).

Marketing status: Prescription Active ingredient EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE Form and strength TABLET;ORAL - 600MG Sponsor CHARTWELL RX Submission history Latest submission status date: 2023-10-03 00:00:00.

Structured Monograph

Clinical summary

Approval overview EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is listed in Drugs@FDA under application 201802 (ANDA). Marketing status: Prescription Active ingredient EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE Form and strength TABLET;ORAL - 600MG Sponsor CHARTWELL RX Submission history Latest submission status date: 2023-10-03 00:00:00. Submission type: ORIG.

Monitoring

  • • Review priority: STANDARD
  • • Marketing status: Prescription

Interaction Notes

  • No interaction notes stored yet.